Dr. John Campbell discusses 'Antiviral game changer' - Merck and Ridgeback.
https://youtu.be/qVW2QqHUJUw
- Oral Antiviral, molnupiravir (MK-4482, EIDD-2801)
- Positive Interim Analysis of Phase 3 Study
- Significantly reduced the risk of hospitalization or death
- During day 1 to 5 to 29 days
- Phase 3 MOVe-OUT trial
https://youtu.be/qVW2QqHUJUw

